Back to GetFilings.com



 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.

 

For the Quarterly Period Ended June 30, 2003

 

Commission File Number 0-18044

 

PROCYTE CORPORATION

(Exact name of the registrant as specified in its charter)

 

Washington

 

91-1307460

(State of incorporation)

 

(I.R.S. Employer Identification No.)

 

 

 

8511 154th Avenue N.E., Redmond, WA

 

98052

(Address of principal executive offices)

 

(Zip code)

 

 

 

Registrant’s telephone number, including area code:

 

(425) 869-1239

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ý

 

No o

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2).

 

Yes o

 

No ý

 

As of August 8, 2003, there were issued and outstanding 15,774,507 shares of common stock, par value $.01 per share.

 

 



 

ProCyte Corporation

 

Index

 

Part I - Financial Information

Item 1. Condensed Consolidated Financial Statements (unaudited)

Balance Sheets - as of June 30, 2003 and December 31, 2002 (unaudited)

Statements of Operations - Three & Six Months Ended June 30, 2003 and 2002 (unaudited)

Statements of Cash Flows – Six Months Ended June 30, 2003 and 2002 (unaudited)

Statements of Stockholders’ Equity – Six Months Ended June 30, 2003 (unaudited)

Notes to Condensed Consolidated Financial Statements (unaudited)

Item 3.  Quantitative and Qualitative Disclosures about Market Risk

Item 4.  Controls and Procedures

Part II - Other Information

Item 1.  Legal Proceedings

Item 2.  Changes in Securities and Use of Proceeds

Item 3.  Defaults Upon Senior Securities

Item 4.  Submission of Matters to a Vote of Security Holders

Item 5.  Other Information

Item 6.  Exhibits and Reports on Form 8-K

Signatures

 

2



 

Part I - Financial Information

 

Item 1. Condensed Consolidated Financial Statements (unaudited)

 

Balance Sheets - as of June 30, 2003 and December 31, 2002 (unaudited)

(in thousands)

 

 

 

 

June 30, 2003

 

December 31, 2002

 

ASSETS

 

 

 

 

 

Cash and cash equivalents

 

$

4,482

 

$

4,556

 

Accounts receivable, net of allowance for doubtful accounts

 

1,176

 

1,328

 

Inventory

 

2,103

 

1,718

 

Prepaid expenses

 

157

 

326

 

Other current assets

 

105

 

3

 

Total current assets

 

8,023

 

7,931

 

Property and equipment, net

 

1,188

 

1,286

 

Intangible assets, net

 

2,895

 

2,903

 

Note due from sale of contract manufacturing operations, net

 

1,841

 

1,826

 

Other assets

 

40

 

143

 

Total Assets

 

$

13,987

 

$

14,089

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Accounts payable, trade

 

$

325

 

$

277

 

Accrued salaries and benefits

 

278

 

404

 

Other accrued liabilities

 

196

 

260

 

Deferred revenue

 

19

 

21

 

Total current liabilities

 

818

 

962

 

Other liabilities

 

94

 

91

 

Deferred proceeds on sale of contract manufacturing operations

 

1,083

 

1,217

 

Total Liabilities

 

1,995

 

2,270

 

Common stock and additional paid-in-capital

 

85,339

 

85,312

 

Deferred compensation

 

 

(11

)

Accumulated deficit

 

(73,347

)

(73,483

)

Stockholders’ Equity

 

11,992

 

11,818

 

Total Liabilities and Stockholders’ Equity

 

$

13,987

 

$

14,089

 

 

See notes to condensed consolidated financial statements

 

3



 

Statements of Operations - Three & Six Months Ended June 30, 2003 and 2002 (unaudited)

(in thousands, except per share amounts)

 

 

 

Three months ended
June 30,

 

Six months ended
June 30,

 

 

 

2003

 

2002

 

2003

 

2002

 

Revenues

 

 

 

 

 

 

 

 

 

Product sales

 

$

2,313

 

$

2,915

 

$

5,195

 

$

5,669

 

Licenses and royalties

 

319

 

348

 

783

 

637

 

Total revenues

 

2,632

 

3,263

 

5,978

 

6,306

 

Cost of product sales

 

619

 

1,096

 

1,802

 

2,023

 

Gross profit

 

2,013

 

2,167

 

4,176

 

4,283

 

Operating Expenses

 

 

 

 

 

 

 

 

 

Marketing and selling

 

814

 

779

 

2,213

 

1,550

 

Research, general, and administrative

 

967

 

899

 

1,934

 

1,802

 

Total operating expenses

 

1,781

 

1,678

 

4,147

 

3,352

 

Operating income

 

232

 

489

 

29

 

931

 

Interest and other income

 

37

 

46

 

125

 

93

 

Net income before tax

 

269

 

535

 

154

 

1,024

 

Provision for income tax

 

 

 

(18

)

 

Net income

 

$

269

 

$

535

 

$

136

 

$

1,024

 

Net earnings per share

 

 

 

 

 

 

 

 

 

Basic

 

$

0.02

 

$

0.03

 

$

0.01

 

$

0.07

 

Diluted

 

$

0.02

 

$

0.03

 

$

0.01

 

$

0.06

 

Shares used in per share computation

 

 

 

 

 

 

 

 

 

Basic

 

15,765

 

15,705

 

15,755

 

15,694

 

Diluted

 

16,040

 

16,061

 

15,979

 

16,016

 

 

See notes to condensed consolidated financial statements